Novo has led a $60m series C round for University of Dundee’s Exscientia that also attracted Evotec, Bristol-Myers Squibb, and GT Healthcare Capital.

Exscientia, a UK-based drug discovery technology spinout of University of Dundee, obtained $60m in a series C round today led by pharmaceutical firm Novo Holdings. Drug discovery and development company Evotec, pharmaceutical firm Bristol-Myers Squibb and private equity firm GT Healthcare Capital, through unnamed limited partners, also took part in the round. Incorporated in 2012,…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.